CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis-Reference-Cited by-同舟云学术

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Published:2020-02 Issue:2 Volume:21 Page:250-260
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gao Jennifer J,Cheng Joyce,Bloomquist Erik,Sanchez Jacquelyn,Wedam Suparna B,Singh Harpreet,Amiri-Kordestani Laleh,Ibrahim Amna,Sridhara Rajeshwari,Goldberg Kirsten B,Theoret Marc R,Kluetz Paul G,Blumenthal Gideon M,Pazdur Richard,Beaver Julia A,Prowell Tatiana M

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016

2. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study;Finn;Lancet Oncol,2015

3. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

4. Overall survival with palbociclib and fulvestrant in advanced breast cancer;Turner;N Engl J Med,2018

5. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy;Sledge;J Clin Oncol,2017

Cited by 209 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of novel quinoline scaffold selective estrogen receptor degraders (SERDs) for treatment of ER positive breast cancer with enhanced antiproliferative bioactivity through immunogenic cell death (ICD) effects;European Journal of Medicinal Chemistry;2024-09

2. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer;Breast Cancer Research and Treatment;2024-08-23

3. Exploring Therapeutic Challenges in Patients with HER2-Positive Breast Cancer—A Single-Center Experience;Life;2024-08-18

4. Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and Spain;Future Oncology;2024-08-08

5. CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma;Cancer Letters;2024-08